Mainz Biomed NV (NASDAQ:QUCY) Short Interest Update

Mainz Biomed NV (NASDAQ:QUCY) was the recipient of a large decline in short interest in May. As of May 29th, there was short interest totaling 1,522,115 shares, a decline of 85.5% from the May 14th total of 10,530,990 shares. Based on an average daily trading volume, of 15,034,560 shares, the short-interest ratio is currently 0.1 days. Approximately 10.7% of the shares of the company are sold short.

Mainz Biomed Stock Down 2.0%

Shares of Mainz Biomed stock traded down $0.04 on Wednesday, hitting $2.00. 245,652 shares of the company traded hands, compared to its average volume of 10,334,215. Mainz Biomed has a 52 week low of $0.30 and a 52 week high of $4.93. The company’s 50-day moving average price is $1.38. The firm has a market cap of $29.31 million, a PE ratio of -0.04 and a beta of 2.22.

Mainz Biomed (NASDAQ:QUCY) last posted its earnings results on Tuesday, March 31st. The company reported ($0.02) earnings per share for the quarter. The company had revenue of $0.13 million for the quarter.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. Wall Street Zen raised shares of Mainz Biomed to a “hold” rating in a report on Saturday. Weiss Ratings raised shares of Mainz Biomed from a “sell (e)” rating to a “sell (e+)” rating in a report on Monday, May 11th. Finally, Maxim Group lowered shares of Mainz Biomed from a “strong-buy” rating to a “hold” rating in a research report on Friday, March 6th. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Reduce”.

About Mainz Biomed

Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.